Zeria Pharmaceutical launched Veltassa (patiromer), a once-daily hyperkalemia treatment in-licensed from Swiss-based CSL Vifor, in Japan on March 17. Veltassa, a powder formulation for oral suspension, is a non-absorbed, cation exchange polymer developed by CSL Vifor. It boosts fecal potassium…
To read the full story
Related Article
- Zeria Obtains Japan Rights to Veltassa from Vifor Pharma
March 28, 2018
BUSINESS
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
- NTT Data, Kindai Hospital Validate RWD-Based Patient Screening Technology
May 26, 2026
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





